Tabalumab

N/A

Report date: 2025/08/23 20:00:08

Base Information

Drug NameTabalumab
Drug Alias Name他巴鲁单抗TabalumabumAnti-BAFF MAb他贝芦单抗Anti-BAFF monoclonal antibody +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionB-cell-activating factor/B lymphocyte stimulator inhibitors
TargetsB-cell-activating factor/B lymphocyte stimulator
Therapy Area/IndicationsAutoimmune DiseasesPemphigusScleroderma, Systemic +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[50] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesApplied Molecular Evolution IncEli Lilly And CompanyNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsN/A
Inactive IndicationsAutoimmune DiseasesPemphigusScleroderma, Systemic +[12] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG